Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.